Jaume Bordas Martinez
@jbordasmartinez
Followers
287
Following
311
Media
29
Statuses
257
Researcher, Pulmonologist. Ph.D. candidate. Interstitial Lung Disease. Sleep Disease. Comprehensive management. Telemedicine. Think out of the box
Barcelona, España
Joined July 2020
Revisión #Metotrexate y #EPID en AR, no es el malo de la pelicula después de todo?
💊🛡️🫁 Methotrexate & the RA Lung: Not the Villain after all? Systematic Review 🎯 Objectives •🔍 Assess progression of RA-ILD in patients exposed to methotrexate (MTX) •🫁 Evaluate lung involvement in RA patients without ILD who are exposed to MTX 🧪 Methods •📚
0
9
13
Completamente de acuerdo con mis propias impresiones. La Inteligencia Artificial es muy trabajadora pero muy poco inteligente. Es como un ayudante que sabe más que yo en redacción y en inglés, además es muy voluntariosa con muchas ideas, y algunas (solo una minoría) son buenas.
Are AI Tools Replacing Scientific Writing? Here's what some leading scientists have to say ⤵ Repost & Save (with 𝘤𝘭𝘪𝘱𝘱𝘦.𝘮𝘦) — Tools like ChatGPT are good helpers (but poor creators) — AI can speed up writing (but it's not ready to take over scientific thinking). — The
0
0
1
ERJ Open Research: Individuals on antifibrotic therapy often display a more severe disease profile. Interestingly, there is a considerable diversity of treatments and antifibrotic therapy is only partially applied following formal progression criteria. https://t.co/qGyYMerx1f
0
7
14
NEJM: First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate ⏩MTX noninferior to prednisone for 1st-line treatment ⏩Similar lung function outcomes week 24. ⏩fewer side effects. ⏩ Could guide treatment choice (selected patients) https://t.co/pRebB1G1LM
0
23
59
Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: https://t.co/gjXxPWFpyR
@atscommunity
7
63
187
ERJ: Pirfenidone does not significantly reduce the proportion of patients with post-COVID-19 fibrotic changes after 6 months of treatment. FVC % improvement and % HRCT fibrotic reduction with pirfenidone were not statistically different from placebo. https://t.co/AmGNYMaDsl
2
63
143
Tornem amb una nova agenda de C17 -MPID. Aquest any a Granollers! Gracies @jbordasmartinez per la organització @hospitalclinic
https://t.co/4OBgLLzp6W
0
4
10
Review a practical framework for evaluating patients with diffuse cystic lung diseases in a new #CHESTReview, now available in the February issue of the journal CHEST®: https://t.co/Z8h6JAEeXr
#MedEd #MedTwitter
0
27
76
📕Article Alert📕 Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study 🫁📈 #OpenAccess #PulmonaryFibrosis #RespiratoryResearch Read the Article: https://t.co/JyyHDKqZ6O
0
6
17
🫁 Respirar és un acte tan bàsic i automàtic que sovint el donem per fet... fins que es complica. En aquest nou episodi del vídeopodcast Veus de Bellvitge, la Dra Maria Molina, Cap de secció de la Unitat Funcional d’Insterstici Pulmonar de l’#hbellvitge, ens endinsa en les
1
9
25
Tot un èxit 😃la sessió informativa sobre com consultar convocatòries de Beques i Ajuts a la Intranet👌
0
1
2
💙 Honoring care in Pulmonary Fibrosis during #QualityOfLifeMonth: Managing comorbidities like heart disease & sleep disorders can improve life for patients & caregivers. Key areas: 🌬️ Dyspnoea 🤧 Cough 💪 Fatigue 💙 Anxiety & Depression Let's raise awareness & support!
0
2
8
🗣 @jacobosellares, pneumòleg de l'@hospitalclinic: "Anem cap a un món sense tabac convencional". 👉 A Milà han prohibit fumar al carrer #AltaveuRTVE. ▶️ https://t.co/Es221NC7Nx
1
5
10
Therapy candidate LYT-100 worked better than Esbriet, with fewer side effects, to slow lung function decline in IPF patients, per trial data. https://t.co/Adfgz0V2O7
#pulmonaryfibrosis #idiopathicpulmonaryfibrosis #PFcommunity #pulmonaryfibrosisawareness
0
1
1
The global number of LTx has increased, particularly for pulmonary fibrosis. However, the need for organs is greater than the availability, and transparent and accountable rules for candidate selection and organ allocation must be ensured. @AreHolm
https://t.co/Zg2Y102SoJ
0
6
19
📚 El Dr. Jaume Bordas Martínez defiende su tesis doctoral sobre el impacto clínico y biológico de los trastornos respiratorios del sueño en la fibrosis pulmonar idiopática. Un paso más para mejorar el conocimiento de enfermedades 📌 @hbellvitge @socapnet @idibell_cat
2
6
33
En este interesante artículo se destaca que la edad (>65 años), DLCO predicha baja y el uso de placebo en lugar de tratamiento antifibrótico son factores asociados con el riesgo de exacerbación. También el riesgo de muerte post-agudización a 90 dias es de alrededor un tercio.
ERJOR: Data from the INBUILD trial suggest that acute exacerbations of progressive pulmonary fibrosis may have similar risk factors and prognostic impact as acute exacerbations of idiopathic pulmonary fibrosis https://t.co/72wvI0ID93
0
1
4
ERJOR: Data from the INBUILD trial suggest that acute exacerbations of progressive pulmonary fibrosis may have similar risk factors and prognostic impact as acute exacerbations of idiopathic pulmonary fibrosis https://t.co/72wvI0ID93
0
15
27
